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Alzheimer’s Disease: From Clinical
Tragedy to Reason for Hope
Kenneth Adams
lzheimer’s Disease (AD) is ruthless. At its
earliest stage (Pre-Clinical AD), it begins
wreaking havoc on the brains of patients
without causing clinical symptoms, leaving them
unaware that they need medical counsel. As the
disease progresses, symptoms start to manifest as
episodes of short-term memory impairment, which
are often dismissed as normal cognitive decline
during aging. If not dismissed, these episodes can
instill fright and uncertainty about what the future
holds. This period, referred to as Mild Cognitive
Impairment (MCI) can last months or years before
symptoms worsen to a degree that triggers alarm.

A

In this stage, referred to by clinicians
as Mild AD, individuals’ short-term
memory is clearly impaired and new
symptoms emerge, such as difficulty
speaking and understanding language,
alongside frequent mood swings. Here,
formal diagnosis of AD becomes much
more likely, forcing patients to endure
the anticipation of their looming
dementia. Moreover, the disease also
begins to take a physical and emotional

toll on patients’ loved ones, as assistance with some aspects of daily living
becomes necessary. Mild AD typically lasts 1-2 years before worsening
symptoms qualify it as Moderate AD,
when individuals experience severe
memory loss and exhibit behaviors that
can be emotionally traumatizing to
all involved, such as rambling speech,
delusions, and uninhibited actions. In
the process, patients are robbed of their

Figure 1. Dr. Alois Alzheimer (1864-1915) and his patient Auguste Deter (1850-1906).
Source: Uncredited photos from Wikimedia Commons.
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identities and their families are forced
to watch helplessly. In its final stage,
Severe AD, patients suffer a near complete loss of memory and the ability to
communicate or process information;
they lose their mobility and, eventually,
even their capacity to swallow. From
diagnosis to death, the disease’s duration typically lasts 8-10 years and, sadly,
we lack effective therapeutics to halt, let
alone reverse, the disease’s progression.
As a budding cell biologist exiting graduate school in 2007 and in the process
of discerning the next step in my career,
this heartbreaking reality prompted me
to seek research opportunities to contribute to the fight against this dreaded
disease. This led to a research fellowship
at the Massachusetts General Hospital
Alzheimer’s Disease Research Center,
where I was inspired by a diverse and
collaborative community of physicians,
scientists, and philanthropists who are
devoted to battling AD. We have much
to learn about its underlying pathology
and effective approaches for treatment,
but the commitment and spirit of the
AD research community gives us
hope that one day we can eradicate
the disease.

Tracking the etiology
of AD—from clinical
dementia to plaques
and tangles to betaamyloid aggregation
Given its brutality and prevalence
(more than 5 million people currently
live with AD, a figure that is projected to rise to 13.5 million by 2050),
enormous resources have been put into
biomedical research focused on understanding and treating AD. Effective
treatments have yet to be established;
nonetheless we have learned a great deal
about the pathology that takes place in
the AD brain. The earliest insights were
provided over a century ago by German
physician Alois Alzheimer (18641915), after whom the disease is named
(Figure 1). When his patient, Auguste
Deter (a woman who was suffering
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Figure 2. Coronal brain sections of healthy brain versus AD brain that has undergone severe
atrophy (left) and microscopic analysis of AD brain tissue highlighting the hallmark lesions that
develop in AD brain—plaques and tangles (right). Sources: National Institute of Health, Wikimedia
Commons; LaDu Neurodegeneration Research Lab, University of Illinois Chicago.

From diagnosis to death,
the disease’s duration typically
lasts 8-10 years and, sadly, we
lack effective therapeutics to
halt, let alone reverse, the
disease’s progression.
from dementia) died in 1906, Dr.
Alzheimer performed an autopsy on her
brain and identified three abnormalities
that to this day are regarded as hall
mark features of AD pathology. On a
macroscopic level, Alzheimer observed
that Deter’s brain had undergone severe
atrophy (Figure 2, left), which we now
know results from extensive neuro
degeneration (the death of brain cells
called neurons) that occurs during AD.
Neuron activities are central to the

control and execution of virtually all
human behaviors including those lost in
AD (memory, language and commu
nication skills, information processing,
and mobility). His discovery provided a
clear causal link between brain atrophy
and the clinical symptoms that take
place during the disease. On a micro
scopic level, Alzheimer determined that
Deter’s brain also contained two abnor
mal lesions referred to as plaques and
tangles (Figure 2, right). Importantly,

these observations alone suggested
that Alzheimer’s Disease results from
the accumulation of toxic plaques and
tangles in the brain that cause neuro
degeneration and the clinical symptoms
associated with the disease. Testing this
hypothesis, however, required answers
to several fundamental questions that
Alzheimer could not address due to
the technological limitations of his
time. These questions included: What
are plaques and tangles composed of? How
do they form? Why do they form in brains
of AD patients? Are plaques and tangles
the toxic agents that cause the neurodegen
eration during AD? Or, conversely, might
they be an inconsequential side effect
of the disease process?
Perhaps surprisingly, addressing these
fundamental questions awaited 80
years of progress in our understanding
of biology, development of research
technology, and national commitment
to combating AD. Nevertheless, when
these three developments converged in
the 1980s, they ignited an explosion of
AD research that has continued to pre
sent day. The explosion began in 1984
when researchers identified the core
component of plaques—the protein
beta-amyloid (aka, amyloid-beta and
Aß)—which set the stage for research
ers to determine where it comes from
and how it forms plaques. Subsequent
studies showed that beta-amyloid is
first produced in brain cells as part of
a larger, membrane-embedded pro
tein called APP (Figure 3), which is
regularly cleaved by enzymes, releas
ing beta-amyloid into the surrounding
brain tissue. Critically, in Alzheimer’s
Disease the released beta-amyloid

Figure 3. Schematic depiction of the process of amyloid plaque formation. Sources: National Institute on Aging and Wikispaces.
May 2015
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Figure 4. How microtubules disintegrate with Alzheimer’s Disease. Sources: Alzheimer’s Disease Education and Referral Center, National Institute on Aging
and Wikimedia Commons.

readily aggregates into insoluble
deposits—plaques. Parallel to these
studies on beta-amyloid, researchers
also determined that the core compo
nent of tangles is a protein called tau,
which was already known to play an
essential role in maintaining the health
of neurons through binding (adher
ing to) and stabilizing structures called
microtubules. As depicted in Figure 4,
microtubules are elongated structures
inside neurons that provide stability to
neuronal extensions (called neurites),
a function that is indispensable to
neuronal health and function. During
AD, tau dissociates from microtubules
and aggregates into insoluble deposits
—tangles—resulting in the disassembly
of microtubules and consequent degen
eration of neurites.
This characterization of beta-amyloid
and tau aggregation into plaques and
tangles, respectively, raised several new
questions about AD pathology, many of
which are still being investigated today.
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One that is central not only to our
understanding of the disease, but
also to the development of AD thera
peutics is this: Can the root cause of AD
be attributed to either beta-amyloid aggre
gation into plaques or tau aggregation into
tangles? If one of these events can be
identified as the root cause, then we
can focus resources on therapeutics that
can intervene in that event. In other
words, if beta-amyloid aggregation
represents the triggering event in
AD, then blocking beta-amyloid
aggregation may represent the most
promising approach to treating AD
patients; likewise, if tau aggregation
is the causative event in AD, then
blocking it may prove more effective.
Major progress toward answering this
question started in the early 1990s,
stemming from genetic studies on
several families whose members exhib
ited a rare, inherited form of AD
called familial Alzheimer’s Disease
(or FAD). FAD differs from the most
common form of AD (called sporadic

AD because it arises sporadically in
population without a clear genetic
cause) in that it is passed on through
generations of a family due to the
inheritance of a genetic mutation.
Starting in the 1990s, researchers began
performing genetic analyses on families
with FAD in an attempt to identify the
mutation(s) responsible for the disease.
Since then, more than 200 mutations
have been discovered. Strikingly, all of
these mutations are located within one
of two genes: the gene that produces
APP (see Figure 3); or the one that
produces the protein presenilin, a key
enzyme that cleaves APP to produce
beta-amyloid. Moreover, experimen
tal analysis of these mutations dem
onstrated that they cause a common,
critical effect in the brain: they increase
beta-amyloid aggregation into plaques.
These discoveries, along with studies
proving that plaques and smaller
aggregates of beta-amyloid are toxic
to neurons, led researchers to formulate
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Given its brutality and prevalence
(more than 5 million people
currently live with AD, a figure
that is projected to rise to 13.5
million by 2050), enormous
resources have been put into
biomedical research focused on
understanding and treating AD.

the amyloid cascade hypothesis (Figure 5),
the most significant guiding force in
AD research for the past 20 years.
The amyloid hypothesis posits that
Alzheimer’s Disease is triggered by the
accumulation of small beta-amyloid
aggregates and larger plaques that exert
pathological stress on the surrounding brain tissue. This stress, in turn,
causes additional pathology, including
tangle formation, leading to widespread
neuronal dysfunction and, ultimately,
dementia. Importantly, while inheritance of the APP and presenilin
mutations explain why beta-amyloid
aggregates in the brains of patients with
FAD, the cause of beta-amyloid aggregation in sporadic AD is not yet fully
understood. Given the fact that sporadic
AD constitutes greater than 95% of all
cases, determining its cause is a major
focus of ongoing research.

Three paths to beta-amyloid
aggregation in sporadic
Alzheimer’s Disease
In 1992, an important discovery was
made that now frames our growing understanding of beta-amyloid

Presenilin
FAD mutations

pathology. The discovery was that
although beta-amyloid represents the
major toxic agent in AD, its presence
in the brain is not limited to individuals
with the disease. Rather, beta-amyloid
is produced in the brains of all individuals—young and old, healthy and
diseased—through continuous synthesis and cleavage of APP (see Figure 3).
This is important because it dismisses
simple explanations for AD etiology. Researchers need to pursue more
nuanced explanations for the cause of
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Figure 5. The amyloid cascade hypothesis. Adapted from Figure 1 in Karran et al., “The Amyloid
Cascade Hypothesis for Alzheimer’s Disease” Nature Reviews 10 (2011) 699.
May 2015

beta-amyloid aggregation in AD.
In doing so, three fundamental
“paths” that contribute to beta-amyloid
aggregation in sporadic AD have
been defined.
First, while cleavage of APP occurs
continuously in brain tissue, the rate
of cleavage can vary and is affected by
numerous factors that we now know
contribute to AD pathology. More
specifically, factors that increase the
rate of APP cleavage cause increased
rates of beta-amyloid production,
leading to its accumulation, which can
in turn drive its aggregation (Figure
6A). Second, to balance the ongoing
production of beta-amyloid, brain cells
have concurrent processes to continuously remove or “clear” it from tissue.
Thus, factors that decrease the rate
of beta-amyloid clearance can also
cause its accumulation and aggregation (Figure 6B). Lastly, while no clear
genetic cause for sporadic AD has been
identified, one gene—apolipoprotein E
(or, apoE)—has been demonstrated to
inf luence a person’s chance of developing the disease. The apoE gene exists
in population as three variants referred
to as apoE2, apoE3, and apoE4, all of
which produce a protein that transports
cholesterol throughout the brain. In
1993, it was discovered that individuals
who inherit apoE4 have a 5-10 times
greater risk of developing AD. In addition, brains of AD patients carrying
7
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Figure 6. Three paths to beta-amyloid aggregation in Sporadic Alzeimer’s Disease (Author’s scheme).

apoE4 exhibit significantly more betaamyloid plaques than those of patients
carrying apoE2 or apoE3, suggesting
that apoE4 promotes AD by increasing
beta-amyloid aggregation. Subsequent
studies have demonstrated that, rather
than affecting beta-amyloid generation or clearance, apoE4 protein binds
and enhances its aggregation (Figure
6C). From patient to patient, it is likely
that one or a combination of these
three paths to beta-amyloid aggregation—increased production, decreased
clearance, and inheritance of apoE4—
explains the onset of AD.

Treating Alzheimer’s
Disease—Where are we?
Where aren’t we?
Alongside research directed at characterizing the cause(s) of AD, enormous
effort has also been focused on developing compounds with which to treat or
prevent the disease. Based on the amyloid cascade hypothesis, the therapeutic
approaches considered most promising
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entail administering medications that
will block or reverse beta-amyloid
aggregation in the brain. Of the compounds generated and tested to date,
many have been designed using our
knowledge of the three paths to betaamyloid aggregation. For example,
several compounds have been created
that inhibit the enzymes responsible for
APP cleavage (see Figure 6A), whereas
others enhance beta-amyloid clearance
(see Figure 6B). A third class of compounds has been designed to interfere
with beta-amyloid aggregation directly
(see Figure 6C). Sadly, however, while
many of these compounds have shown
promise in laboratory models of AD,
we have yet to establish one that has
proved effective as a medication in
human clinical trials (due either to
insufficient reduction in beta-amyloid
aggregation or to intolerable toxic side
effects). Therefore, patients and their
families continue to wait for the discovery of a compound that will alleviate
their tragic fear and suffering.

Will the discovery come in form of a
novel medication that blocks the toxic
effects of beta-amyloid aggregates? Or
will it come from advances in our
knowledge of AD pathology that push
our focus beyond beta-amyloid and
its toxic aggregation? For now, it is
impossible to predict it with much
certainty. I nevertheless remain optimistic that the spirit and commitment
I encountered within the AD research
community when I entered it in
2007 is stronger than ever and will
one day prevail.

Kenneth Adams is Assistant Professor in the
Department of Biological Sciences.
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